Subscribe
shutterstock_olivier_le_moal_756213100
Olivier Le Moal / Shutterstock.com
19 March 2020AmericasRory O'Neill

PacBio pledges to fight invalidation of patents after bitter dispute

California-based  Pacific Biosciences (PacBio) has accused a UK rival of exploiting the coronavirus pandemic in a patent infringement trial.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
Personal Genomics takes PacBio dispute to Chinese court
22 May 2020   Taiwanese biotechnology company Personal Genomics is using California’s Pacific Biosciences for patent infringement in China.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Asia
Personal Genomics takes PacBio dispute to Chinese court
22 May 2020   Taiwanese biotechnology company Personal Genomics is using California’s Pacific Biosciences for patent infringement in China.

More on this story

Asia
Personal Genomics takes PacBio dispute to Chinese court
22 May 2020   Taiwanese biotechnology company Personal Genomics is using California’s Pacific Biosciences for patent infringement in China.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?